Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression

Brain bioenergetic abnormalities have been observed frequently in adults with major depressive disorder (MDD); however, results have been inconsistent regarding whether decreased or increased metabolism was observed. Phosphorus-31 magnetic resonance spectroscopy (31P MRS) allows for the quantification of bioenergetic molecules, containing high-energy phosphates, over the whole brain as well as measuring the differences between gray matter and white matter. We recruited 50 subjects with a current diagnosis of MDD, not currently treated with psychotropic medication, between ages of 18 and 65 (mean±SD age: 43.4±13.6; 46% female) and 30 healthy volunteers, matched for age and gender (39.0±12.5 years of age; 36.6% female). All subjects received a T1 MP-FLASH scan for tissue segmentation followed by 31P MRS, chemical shift imaging scan with 84 voxels of data collected over the entire brain utilizing a dual-tuned, proton-phosphorus coil to minimize subject movement. Phosphocreatine and inorganic phosphate (Pi) varied in opposite directions across gray matter and white matter when MDD subjects were compared with controls. This finding suggests alterations in high-energy phosphate metabolism and regulation of oxidative phosphorylation in MDD patients. In addition, within the MDD group, gray matter Pi, a regulator of oxidative phosphorylation, correlated positively with severity of depression. These data support a model that includes changes in brain bioenergetic function in subjects with major depression.

[1]  M. Raichle,et al.  A functional anatomical study of unipolar depression , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  R. Davies,et al.  PHOSPHORYLCREATINE CONSUMPTION DURING SINGLE-WORKING CONTRACTIONS OF ISOLATED MUSCLE. , 1965, Biochimica et biophysica acta.

[3]  I. Silver,et al.  ATP and Brain Function , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  M Davies,et al.  The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. , 1992 .

[5]  G. Rajkowska,et al.  Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder , 2016, Neuroscience.

[6]  R. Shelton,et al.  Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development , 2013, The Australian and New Zealand journal of psychiatry.

[7]  F. Jeanneteau,et al.  Linking Mitochondria to Synapses: New Insights for Stress-Related Neuropsychiatric Disorders , 2016, Neural plasticity.

[8]  M J Kushmerick,et al.  A simple analysis of the "phosphocreatine shuttle". , 1984, The American journal of physiology.

[9]  A. Lehninger.  Principles of Biochemistry , 1984 .

[10]  A. Alavi,et al.  Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ravi S. Menon,et al.  In vivo brain 31P‐MRS: measuring the phospholipid resonances at 4 Tesla from small voxels , 2002, NMR in biomedicine.

[12]  M. Raichle,et al.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.

[13]  P. Fox,et al.  Cingulate function in depression: a potential predictor of treatment response , 1997, Neuroreport.

[14]  J. Price,et al.  Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Westfall,et al.  Gatekeeping strategies for clinical trials that do not require all primary effects to be significant , 2003, Statistics in medicine.

[16]  Perry F. Renshaw,et al.  Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder , 2008, Biological Psychiatry.

[17]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[18]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[19]  M. Frye,et al.  Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders , 1999, Biological Psychiatry.

[20]  Herta Flor,et al.  A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression , 2012, NeuroImage.

[21]  N. V. van Riel,et al.  Prediction of Muscle Energy States at Low Metabolic Rates Requires Feedback Control of Mitochondrial Respiratory Chain Activity by Inorganic Phosphate , 2012, PloS one.

[22]  H N Wagner,et al.  Paralimbic hypoperfusion in unipolar depression. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  P. Renshaw,et al.  31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression , 2009, International journal of geriatric psychiatry.

[24]  R. Parsey,et al.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment , 2009, Psychiatry Research: Neuroimaging.

[25]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[26]  S. Alborzian,et al.  Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine , 1999, Psychiatry Research: Neuroimaging.

[27]  J T Vaughan,et al.  Evaluation of 31P metabolite differences in human cerebral gray and white matter , 1998, Magnetic resonance in medicine.

[28]  R. Balaban.  Domestication of the cardiac mitochondrion for energy conversion. , 2009, Journal of molecular and cellular cardiology.

[29]  M. Wyss,et al.  Creatine and creatinine metabolism. , 2000, Physiological reviews.

[30]  M. Iyengar.  Creatine kinase as an intracellular regulator , 1984, Journal of Muscle Research & Cell Motility.

[31]  R. Balaban,et al.  Metabolic Network Control of Oxidative Phosphorylation , 2003, Journal of Biological Chemistry.

[32]  J. Mazziotta,et al.  Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.

[33]  T. Inubushi,et al.  Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. , 1992, Journal of affective disorders.

[34]  P F Renshaw,et al.  Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. , 1997, The American journal of psychiatry.

[35]  M. Wyss,et al.  Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. , 1992, The Biochemical journal.

[36]  G. L. Kenyon,et al.  Creatine Kinase: Structure‐Activity Relationships , 2006 .

[37]  a.R.V..  Neuroglia , 1956, Neurology.

[38]  S Nioka,et al.  Multiple controls of oxidative metabolism in living tissues as studied by phosphorus magnetic resonance. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P F Renshaw,et al.  Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. , 2001, The American journal of psychiatry.

[40]  R. Kellner.  A symptom questionnaire. , 1987, The Journal of clinical psychiatry.

[41]  G. Rajkowska,et al.  Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. , 2013, Current drug targets.

[42]  R. Post,et al.  Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression , 2005, Biological Psychiatry.

[43]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[44]  P. Renshaw,et al.  Tissue-specific differences in brain phosphodiesters in late-life major depression. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[45]  Stefan Riehemann,et al.  31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[46]  P. Jerabek,et al.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.

[47]  Louis Sokoloff,et al.  Circulation and Energy Metabolism of the Brain , 1999 .

[48]  Jullie W Pan,et al.  Quantitative 31P spectroscopic imaging of human brain at 4 Tesla: Assessment of gray and white matter differences of phosphocreatine and ATP , 2001, Magnetic resonance in medicine.